ADHD

A recent study found that athletes with attention deficit hyperactivity disorder (ADHD) may need to be even more cautious in concussion prevention.

Both asthma and attention-deficit/hyperactivity disorder (ADHD), both chronic conditions, have been associated with each other in previous studies, but questions remained as to the strength of the association because of other possible confounders.

New research suggests psychiatric diseases that affect a patient’s ability to appropriately respond to stimuli may be triggered by the misplacement of an enzyme in the pathway within neurons.

New research suggests psychiatric diseases, including ADHD, that affect a patient’s ability to appropriately respond to stimuli may be triggered by the misplacement of an enzyme in the pathway within neurons.

Prescription medication use for attention-deficit/hyperactivity disorder (ADHD), asthma, and contraception have all increased in children and teens.

Attention-deficit/hyperactivity disorder is a neurodevelopmental mental disorder characterized by difficulty paying attention, excessive activity, and/or impulsivity that interferes with development and/or functioning.

Many patients with ADHD report peers seeking nonmedical prescription stimulant use.

More research needed to determine if ADHD medication is safe to take before and during pregnancy.

Use of drugs that treat attention-deficit/hyperactivity disorder increased among all age groups and in all US geographic regions.

Study finds that ADHD treatment recommendations are not always followed.

Acetaminophen use for 29 days or more during pregnancy linked to a significant risk of attention-deficit/hyperactivity disorder.

Top articles of the week from The American Journal of Pharmacy Benefits.

Children with ADHD treated with AKL-T01 showed a significant positive improvement in attention.

Between 10% and 20% of students in kindergarten through high school have chronic illness.

The fda has approved mydayis (mixed salts of a single-entity amphetamine product, by Shire) to treat attention deficit hyperactivity disorder (ADHD) in patients 13 years or older.

Guanfacine (Intuniv) for attention-deficit hyperactivity disorder (ADHD) shows marked clinical improvement in global functioning.

Methylphenidate (Cotempla XR-ODT) extended-release orally disintegrating tablets approved to treat children with attention-deficit/hyperactivity disorder.

Mydayis is not for use in children 12 years and younger.

The FDA has approved Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets from Neos Therapeutics, the company announced in a press release.

Female rats observed to be especially susceptible to methylphenidate-related behavioral changes.

Four pharmaceutical companies gained approval for atomoxetine (Strattera).

The FDA today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder.

Top news of the day from across the health care landscape.

This article highlights 5 published case reports that document unusually high doses of medications that are not often seen in clinical practice.

A recent study has indicated that even small amounts of exercise can have psychological benefits for adults who experience ADHD symptoms.

Although children and teenagers who are diagnosed with attention-deficit/hyperactivity disorder are more likely to engage in risky behaviors such as dangerous driving and drug use, a recent study has suggested that the use of ADHD medications could help prevent these behaviors.

Metadoxine Extended Release did not meet the primary endpoint in a study analysis for attention deficit hyperactivity disorder.

The drug failed to demonstrate a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).

Mylan launched 2 generic pharmaceutical products at the end of December for the treatment of attention deficit hyperactivity disorder (ADHD) and the prevention of pregnancy.